RxDoctor Payments Data

Thomas Merriman, MD

Interventional Pain Medicine · Amarillo, TXNPI 1134179054

Payments from drug & device makers

$7,401in general payments, 2019–2025

Across 258 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$2K
  • Collegium Pharmaceutical, Inc.$311
  • Amgen$116
  • Biodelivery Sciences International, Inc.$86
  • Novartis$80
  • plus $606 from 18 others

What the payments were for

  • Travel & lodging$1,65722%
  • Food & beverage$5,74478%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,401 in reported general payments places this provider in the 50th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$514,419
Medicare patients
718
Services billed
5,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,583$46,863
NucyntaTapentadol Hcl23$25,065
Xtampza ErOxycodone Myristate19$18,700
OxycontinOxycodone Hcl22$17,900
Buprenorphine64$17,168
Morphine Sulfate ErMorphine Sulfate240$8,399
Fentanyl63$7,191
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen262$6,154
Oxycodone Hcl124$3,129
Pregabalin98$2,035
Acetaminophen-CodeineAcetaminophen With Codeine85$1,572
Morphine Sulfate78$1,551
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$1,338
Cyclobenzaprine Hcl58$1,206
Gabapentin108$1,149

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$311$43,76542 claims
Upsher-smith Laboratories LLCTopiramate$16$6016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →